Target intelligence / Profile preview

Toll-like receptor 1 and Toll-like receptor 2 (TLR1 and TLR2)

Target
TLR1 and TLR2
Molecular classification
Receptor, Pattern recognition receptor (PRR), Type I transmembrane protein, Innate immune receptor, Toll-interleukin receptor (TIR) domain receptor
01

Overview

Toll-like receptor 1 and Toll-like receptor 2 (TLR1 and TLR2) are cell-surface pattern recognition receptors that play a critical role in the innate immune system by detecting pathogen-associated molecular patterns (PAMPs) from bacteria, fungi, and other microbes[1][2][5][6][7]. Both are type I transmembrane proteins with extracellular leucine-rich repeat (LRR) domains for ligand recognition, a single transmembrane helix, and an intracellular Toll/interleukin-1 receptor (TIR) domain for signal transduction[5][6]. TLR1 and TLR2 commonly function as a heterodimer, recognizing bacterial lipoproteins and lipopeptides and initiating MyD88-dependent (and to a lesser extent, TRIF-dependent) intracellular signaling cascades[3][4][7]. Their activation results in the production of pro-inflammatory cytokines, linking the innate and adaptive immune response, but their dysregulation is implicated in infectious, inflammatory, and autoimmune diseases[6][7][1]. If you need further breakdown for each individual receptor (TLR1 or TLR2), specify which, as both frequently function together as a heterodimer for ligand recognition and downstream signaling[5][3].

Other names
TLR1TLR2toll/interleukin-1 receptor-like protein 1toll/interleukin-1 receptor-like protein 2CD281 (TLR1)CD282 (TLR2)
02

Mechanism of action

Agonists: Trigger TLR1/2 dimerization and downstream MyD88-dependent signaling, promoting immune response Antagonists: Block ligand binding, preventing receptor activation and reducing inflammation

03

Biological functions

Immune responsePathogen recognitionSignal transductionInflammationBridging innate and adaptive immunityCytokine production
04

Disease associations

InfectionInflammationAutoimmune diseaseCancerCardiovascular disease
05

Safety considerations

Risk of overstimulation leading to excessive inflammation or cytokine stormPotential for autoimmunity if self-antigens are inappropriately recognizedImmunosuppression if signaling is chronically inhibited
06

Interacting drugs

Pam3CSK4 (synthetic triacylated lipopeptide agonist)

2 more in the full profile.

07

Biomarkers

TLR1 and TLR2 expression on immune cells as a marker of activation status or disease activitySerum cytokine levels (e.g., TNF-α, IL-6) induced by TLR1/2 signaling

Beyond the preview

Go deeper on Toll-like receptor 1 and Toll-like receptor 2 (TLR1 and TLR2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Toll-like receptor 1 and Toll-like receptor 2 (TLR1 and TLR2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call